Filing Flows › Anika Therapeutics (ANIK) › Q3 2026 › vs Q3 2025
Anika Therapeutics (ANIK) Q3 2026 vs Q3 2025 (year over year)
Anika Therapeutics's revenue rose $2.8M (+10%) from $27.8M in Q3 2025 to $30.6M in Q3 2026. The biggest changes: Commercial Channel +$2.0M (+17%); OEM Channel +$757K (+5%).
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 22.0% | 17.9% | +4.0 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| OEM Channel | $16.6M | $15.8M | $757K | +5% |
| Commercial Channel | $14.0M | $12.0M | $2.0M | +17% |
| Revenue | $30.6M | $27.8M | $2.8M | +10% |
| Other income, net | $390K | $1.8M | −$1.5M | -79% |
| Income tax benefit | $11K | −$939K | $950K | — |
| Net loss | $311K | $2.3M | −$2.0M | -87% |
| Costs & expenses | $31.3M | $32.0M | −$683K | -2% |
| Operating costs | $31.3M | $31.1M | $256K | +0.8% |
| Cost of revenue | $11.8M | $12.2M | −$476K | -4% |
| Research & development | $7.9M | $6.9M | $949K | +14% |
| SG&A | $11.7M | $11.9M | −$217K | -2% |
| Operating cash sources | $8.7M | $9.2M | −$511K | -6% |
| Depreciation & amortization | $1.4M | $1.4M | $48K | +3% |
| Share-based compensation | $4.2M | $2.2M | $2.0M | +92% |
| Working capital & other | $3.0M | $5.6M | −$2.6M | -46% |
| Net loss absorbed | $311K | $2.3M | −$2.0M | -87% |
| Operating cash flow | $8.4M | $6.9M | $1.5M | +22% |
| Free cash flow (OCF − capex) | $6.7M | $5.0M | $1.7M | +35% |
| Capital expenditures | $1.7M | $1.9M | −$226K | -12% |
Questions
How much did Anika Therapeutics's revenue grow year over year in Q3 2026?
Anika Therapeutics's revenue rose $2.8M (+10%) from $27.8M in Q3 2025 to $30.6M in Q3 2026.
What drove Anika Therapeutics's revenue change in Q3 2026?
Commercial Channel +$2.0M (+17%); OEM Channel +$757K (+5%).